Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the safest dose of recombinant surfactant protein D
(drug name: rfhSP-D) that can be administered to preterm infants born at less than 28 weeks
gestation, and to help identify whether this can prevent the development of neonatal chronic
lung disease.
Phase:
Phase 1
Details
Lead Sponsor:
University College, London
Collaborator:
Medical Research Council
Treatments:
Pulmonary Surfactant-Associated Protein D Pulmonary Surfactants